HR+ breast cancer
Oncology · 2005–2009
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| goserelin acetate Hormone-dependent early breast cancer in peri or pre-menopausal women as an alternative to adjuvant chemotherapy or oophorectomy. | Nov 2009 | Recommended with restriction | no section in document |
| letrozole Extended adjuvant treatment of early-stage hormone-dependent breast cancer in post-menopausal women who have completed no less than 4.5 years of standard… | Nov 2005 | Not recommended | no section in document |
What the PBS pays
$65M in government benefit over 2024–25, across 399,887 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| goserelin acetate | $60.7M |
| letrozole | $4.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.